Jane Street Group LLC Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Jane Street Group LLC increased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 59.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,041 shares of the company's stock after purchasing an additional 81,193 shares during the quarter. Jane Street Group LLC owned approximately 0.24% of Arcus Biosciences worth $3,319,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System boosted its stake in shares of Arcus Biosciences by 2.6% during the second quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company's stock valued at $419,000 after purchasing an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Arcus Biosciences by 2.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company's stock worth $471,000 after buying an additional 843 shares during the period. WINTON GROUP Ltd grew its holdings in Arcus Biosciences by 3.3% during the 2nd quarter. WINTON GROUP Ltd now owns 59,137 shares of the company's stock worth $901,000 after acquiring an additional 1,872 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Arcus Biosciences by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 58,173 shares of the company's stock valued at $886,000 after acquiring an additional 1,951 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Arcus Biosciences by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company's stock valued at $455,000 after acquiring an additional 2,123 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Up 0.3 %

Shares of Arcus Biosciences stock traded up $0.04 during trading on Friday, reaching $15.50. 2,023,196 shares of the company traded hands, compared to its average volume of 734,758. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market capitalization of $1.42 billion, a PE ratio of -4.92 and a beta of 0.88. The company has a 50 day moving average price of $16.41 and a 200-day moving average price of $16.06. Arcus Biosciences, Inc. has a 1-year low of $13.52 and a 1-year high of $20.31.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $48.00 million during the quarter, compared to the consensus estimate of $38.95 million. During the same period last year, the business posted ($0.94) EPS. The firm's revenue for the quarter was up 50.0% compared to the same quarter last year. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RCUS has been the topic of several analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. HC Wainwright reissued a "neutral" rating and issued a $20.00 price target on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Barclays lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Finally, Wells Fargo & Company initiated coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an "overweight" rating and a $29.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Arcus Biosciences presently has an average rating of "Buy" and an average price target of $34.00.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.